NEW YORK (GenomeWeb) — Biotheranostics announced today that its Breast Cancer Index (BCI) genomic test has has been issued an expanded local coverage determination (LCD) by Medicare contractor Noridian.
The PCR-based test evaluates the expression of 11 genes to help physicians predict the risk of late disease recurrence and identify which early-stage breast cancer patients are likely to benefit from continuing adjuvant endocrine therapy beyond five years.